Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2024 | Advances being made in high-risk smoldering myeloma: ongoing trials & promising agents

Irene Ghobrial • 25 Sep 2024
IMS 2024
Rare Diseases Smoldering Myeloma Antibodies Bortezomib CAR-T Carfilzomib Daratumumab Dexamethasone Ixazomib Lenalidomide Teclistamab
ImmunoPRISM

Irene Ghobrial, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, gives an overview of ongoing trials and promising agents being explored in high-risk smoldering multiple myeloma (HR-SMM), including triplet and quadruplet regimens, bispecific antibodies, and CAR T-cells. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Irene Ghobrial

Risk stratification in smoldering myeloma: current standards and emerging advances 1:05
Risk stratification in smoldering myeloma: current standards and emerging advances
Irene Ghobrial • 17 Sep 2025
Controversies and unanswered questions in smoldering myeloma and MGUS 0:53
Controversies and unanswered questions in smoldering myeloma and MGUS
Irene Ghobrial • 17 Sep 2025
The potential of circulating tumor cells to clinically assess multiple myeloma and its precursors 0:51
The potential of circulating tumor cells to clinically assess multiple myeloma and its precursors
Irene Ghobrial • 17 Sep 2025
Wrap-up of the 2025 Intercepting Blood Cancers Workshop 0:50
Wrap-up of the 2025 Intercepting Blood Cancers Workshop
Irene Ghobrial • 13 Mar 2025

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Updates on current research exploring treatment strategies for high-risk smoldering myeloma 2:14
Updates on current research exploring treatment strategies for high-risk smoldering myeloma
Karthik Ramasamy • 15 Sep 2025
Updates on myeloma research from IMS 2025: advances in frontline and R/R treatment 4:27
Updates on myeloma research from IMS 2025: advances in frontline and R/R treatment
Claudio Cerchione • 18 Sep 2025
Performance of a novel prognostic index for multiple and smoldering myeloma 1:49
Performance of a novel prognostic index for multiple and smoldering myeloma
Claudio Cerchione • 18 Sep 2025
The content of VJHemOnc is intended for healthcare professionals